Received Jul 1, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| ADEN_4_7 | ADENOVIRUS TYPES 4 & 7, LIVE, ORAL (NO BRAND NAME) | TEVA PHARMACEUTICALS | 1 | — | PO / MO |
| FLU3 | INFLUENZA (SEASONAL) (AFLURIA) | SEQIRUS, INC. | UNK | — | IM |
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | UNK | — | IM |
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | — | IM |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | IM |
| MNQ | MENINGOCOCCAL CONJUGATE (MENQUADFI) | SANOFI PASTEUR | 1 | — | IM |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | IM |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | — | — |
Patient has what appears to be a leukocytoclastic vasculitis type rash. The etiology is unclear at this time. He had associated fever; now resolved. Blood cultures reveal no growth to date. He received multiple vaccines on 5/21/2025 and 5/27/2025. He has had a cough for the past 6 or 7 weeks. This rash could represent a vaccine reaction or signs/symptoms from a viral syndrome. He appears to be improving off antibiotic therapy.
None
None
Acetaminophen and carboxymethylcellulose eye drops
None